OncoMatch/Clinical Trials/NCT04501120
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Is NCT04501120 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for relapsed/refractory acute myeloid leukaemia.
Treatment: Lisaftoclax (APG-2575) · Reduced-dose HHT · standard-dose HHT · Azacitidine · Lisaftoclax (APG-2575) · olverembatinib — The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: BCR BCR-ABL1
t(9;22)(q34.1;q11.2); BCR-ABL1 positive AML patients
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Prior history of allogeneic hematopoietic stem cell transplantation
Cannot have received: adoptive cell immunotherapy
adoptive cell immunotherapy
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 12 months
autologous hematopoietic stem cell transplantation within 12 months
Cannot have received: chemotherapy (hydroxyurea)
Exception: hydroxyurea permitted more than 24 hours before first dose
Within 14 days before the first dose of study drug, received chemotherapy (hydroxyurea is permitted more than 24 hours before the first dose of study drug)
Cannot have received: radiotherapy
Within 14 days before the first dose of study drug, received ... radiotherapy
Cannot have received: surgery
Within 14 days before the first dose of study drug, received ... surgery
Cannot have received: immunotherapy
Within 14 days before the first dose of study drug, received ... immunotherapy
Cannot have received: targeted therapy
Within 14 days before the first dose of study drug, received ... targeted therapy
Cannot have received: biological therapy
Within 14 days before the first dose of study drug, received ... biological therapy
Cannot have received: investigational treatment
Within 14 days before the first dose of study drug, received ... any investigational treatment
Lab requirements
Kidney function
adequate renal function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify